Ligand Pharmaceuticals Inc.
) inked a deal with
TG Therapeutics, Inc.
) to develop and commercialize Ligand's Interleukin-1 Receptor
Associated Kinase-4 (IRAK-4) inhibitors. Ligand Pharma is currently
developing IRAK4 inhibitors for the treatment of certain forms of
cancer and autoimmune diseases. The IRAK4 program is in
According to the deal, Ligand Pharma will receive 125,000
unregistered shares of TG Therapeutics' common stock, valued at
about $1 million on the date of signing the deal. Additionally, the
company will receive $207 million on the achievement of specific
milestones and tiered royalties of 6%−9.5% on net sales of licensed
Ligand Pharma stated in its press release that the IRAK4 program
complements TG Therapeutics' hematological malignancy candidates,
TG-1101 (ublituximab) and TGR-1202 (a PI3K delta inhibitor). If
successfully developed, IRAK4 inhibitors will strongly benefit
patients suffering from certain B-cell malignancies.
We are positive on the agreement between Ligand Pharma and TG
Therapeutics. The agreement should be beneficial for Ligand Pharma
since it gains a strong partner in the form of TG Therapeutics.
Ligand Pharma is working toward strengthening its pipeline and has
inked quite a few deals in the last few months. In May 2014, Ligand
Pharma signed a licensing and research deal with
) under which both companies will develop candidates utilizing
Ligand Pharma's LTP technology platform for the treatment of
dyslipidemia, including hypertriglyceridemia. Late last month,
Ligand Pharma licensed the rights to five programs to Viking
Ligand Pharma holds a Zacks Rank #3 (Hold). A better-ranked stock
in the biotech sector is
Biogen Idec Inc.
), carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ASTRAZENECA PLC (AZN): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
LIGAND PHARMA-B (LGND): Free Stock Analysis
TG THERAPEUTICS (TGTX): Free Stock Analysis
To read this article on Zacks.com click here.